MiR-371a-3p in cystic trophoblastic tumour of the testis: supporting a maturation phenomenon towards teratoma
Corresponding Author
João Lobo
Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
Search for more papers by this authorNuno Tiago Tavares
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Search for more papers by this authorDaniela Barros-Silva
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Search for more papers by this authorAlina Rosinha
Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
Search for more papers by this authorAntónio Morais
Department of Urology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
Search for more papers by this authorCarmen Jerónimo
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
Search for more papers by this authorÂngelo Rodrigues
Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
Search for more papers by this authorRui Henrique
Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
Search for more papers by this authorCorresponding Author
João Lobo
Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
Search for more papers by this authorNuno Tiago Tavares
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Search for more papers by this authorDaniela Barros-Silva
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Search for more papers by this authorAlina Rosinha
Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
Search for more papers by this authorAntónio Morais
Department of Urology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
Search for more papers by this authorCarmen Jerónimo
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
Search for more papers by this authorÂngelo Rodrigues
Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
Search for more papers by this authorRui Henrique
Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Porto, Portugal
Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), Porto, Portugal
Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), Porto, Portugal
Search for more papers by this authorJoão Lobo and Nuno Tiago Tavares are joint first authors.
Ângelo Rodrigues and Rui Henrique are joint senior authors.
Conflict of interest
The authors declare that they have no conflicts of interest.
Open Research
Data availability statement
The data that support the findings of this study are available in the supplementary material of this article.
Supporting Information
| Filename | Description |
|---|---|
| his14929-sup-0001-DataS1.docxWord 2007 document , 25.3 KB | Table S1. Clinicopathological features of the cases included in the study. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Ulbright TM, Henley JD, Cummings OW, Foster RS, Cheng L. Cystic trophoblastic tumor: a nonaggressive lesion in postchemotherapy resections of patients with testicular germ cell tumors. Am. J. Surg. Pathol. 2004; 28; 1212–1216.
- 2Wang ML, McHugh JB, Weizer AZ et al. Rare presentation of metastatic cystic trophoblastic tumor in a patient without prior chemotherapy. Urol. Case Rep. 2017; 13; 154–157.
- 3Gondim DD, Ulbright TM, Cheng L, Idrees MT. Primary cystic trophoblastic tumor of the testis: a study of 14 cases. Am. J. Surg. Pathol. 2017; 41; 788–794.
- 4Gadde R, Arora K, Felicella MM et al. Cystic trophoblastic tumor in a primary central nervous system postchemotherapy germ cell tumor: the first case report. Int. J. Surg. Pathol. 2020; 28; 925–928.
- 5Looijenga LH, Van der Kwast TH, Grignon D et al. Report from the ISUP consultation conference on molecular pathology of urogenital cancers: IV. Am. J. Surg. Pathol. 2020; 44; e66.
- 6Vilela-Salgueiro B, Barros-Silva D, Lobo J et al. Germ cell tumour subtypes display differential expression of microrna371a-3p. Philos. Trans. R. Soc. B: Biol. Sci. 2018; 373; 20170338.
Citing Literature
